Evidence map›Paper›PMID 32854983›Full record

ArticleJournal of substance abuse treatment2020

Adaptation of contingency management for stimulant use disorder during the COVID-19 pandemic.

Evelyn Zastepa, Jane C Sun, Jennifer Clune, Nickie Mathew

Open access · bronzeAbstract read
In one paragraph

Article in Journal of substance abuse treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Integrated Care Models: HIV and Substance Use.Current HIV/AIDS reports · 2023
    Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Evelyn ZastepaFaculty of Medicine, University of British Columbia, Department of Psychiatry, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada. Electronic address: evelyn.zastepa@alumni.ubc.ca.
Jane C SunProvincial Health Services Authority, British Columbia Mental Health and Substance Use Services, 4949 Heather St, Vancouver, BC V5Z 3L7, Canada. Electronic address: jane.sun1@phsa.ca.
Jennifer CluneFaculty of Medicine, University of British Columbia, Department of Psychiatry, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada. Electronic address: jclune@alumni.ubc.ca.
Nickie MathewFaculty of Medicine, University of British Columbia, Department of Psychiatry, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada; Burnaby Centre for Mental Health and Addiction, 3405 Willingdon Ave, Burnaby, BC V5G 3H4, Canada. Electronic address: nick.mathew@phsa.ca.
University of British Columbia · CAProvincial Health Services Authority · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current coronavirus disease (COVID-19) pandemic has rapidly spread across the world. Individuals with stimulant use disorder are a vulnerable population, who are particularly at risk of negative outcomes during this pandemic due to several risk factors, including mental and physical comorbidities, weakened immune responses, high-risk behaviors, and barriers to healthcare access. Engaging patients with stimulant use disorder in regular treatment has become even more difficult during this pandemic, which has resulted in many cuts to addiction treatment programs. The most effective treatment options for stimulant use disorder are psychosocial interventions, which rely heavily on in-person interactions, posing an added challenge during physical distancing. In particular, contingency management (CM) is a behavioral therapy that utilizes tangible reinforcements to incentivize targeted behavior changes, and is an effective treatment intervention used for stimulant use disorder. This paper highlights the treatment challenges for individuals with stimulant use disorder and the importance of adapting CM programs during COVID-19. We present strategies for how CM can be adapted and its role expanded in a safe way during the COVID-19 pandemic to help prevent infection spread, stimulant use relapse, and worsened psychosocial consequences.

Indexed as

Behavior TherapyCentral Nervous System StimulantsCoronavirus InfectionsCOVID-19HumansPandemicsPneumonia, ViralRisk FactorsSubstance-Related DisordersVulnerable PopulationsCentral Nervous System StimulantsAmphetamineCocaineContingency managementCOVID-19Stimulant

Identifiers

PMID32854983
PMCPMC7417964
OpenAlexW3048369146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.